In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Internal Medicine"
DOI: 10.7326/j23-0020
Abstract: SOURCE CITATION Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245. read more here.
Keywords: ill patients; critically ill; covid receptor; antagonists reduced ... See more keywords